We demonstrate that KRAS mutants induce chemoresistance in NSCLC by amplifying EKR/JNK signaling-mediated ALKBH5 posttranslational modifications (PTMs), including phosphorylation and SUMOylation. Here, ALKBH5 is linked to non-small cell lung carcinoma.